Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: Implications for implementing evidence-based use of glucose-lowering medications

Felona Gunawan, Michael E. Nassif, Caitlin Partridge, Tariq Ahmad, Mikhail Kosiborod, Silvio E. Inzucchi

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in type 2 diabetes (T2D) patients. Recent cardiovascular outcome trials demonstrated clear cardiovascular benefits of novel classes of glucose-lowering agents. We performed retrospective electronic health record review at two major healthcare systems in the USA to determine the relative frequencies of outpatient encounters (hence prescribing opportunities) that a patient with T2D and CVD had with a cardiologist vs. an endocrinologist over one-year period. Of 109 747 T2D patients, 42.6% had established CVD. The ratio of cardiology-to-endocrinology outpatient encounters was 2.0:1 for all T2D patients, and 4.1:1 for those with T2D and CVD. Because each outpatient encounter provides an opportunity to discuss glucose-lowering medications with cardiovascular benefits, the much greater frequency of cardiology encounters highlights the emerging potential for cardiovascular specialists to influence or even implement evidence-based glucose-lowering therapies, thereby improving cardiovascular outcomes in their T2D patients.

Original languageEnglish (US)
Pages (from-to)56-59
Number of pages4
JournalCardiovascular Endocrinology and Metabolism
Volume9
Issue number2
DOIs
StatePublished - 2020
Externally publishedYes

Keywords

  • cardiologist
  • cardiovascular disease
  • endocrinologist
  • type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: Implications for implementing evidence-based use of glucose-lowering medications'. Together they form a unique fingerprint.

Cite this